What are cardiologists saying about GLP-1 drugs on podcasts?

Cardiologists on podcasts this year mostly say GLP-1s have changed from "weight-loss drugs" into heart medicines. Several describe going from skeptic to prescriber. They also raise three concerns: tirzepatide doesn't yet have the same heart-outcome proof as semaglutide, there's no long-term data, and people without obesity are taking them off-label. I searched January–October 2026 and kept only segments with a guest coded as a cardiologist. The quotes below are the cardiologists' own lines, not the hosts'.

1. "These are heart drugs, not just weight-loss drugs"

• Micah Eimer, In the Loop with Sasha-Ann Simons ("What Have We Learned About GLP-1s?", Jul 15): he says cardiologists' first reaction to any weight-loss drug used to be "No way," because of the history of drugs like Fen-Phen. He changed his mind once he thought of them as metabolic medicines: "I would never withhold cholesterol medicine… why am I not using it?" (2:27). He also said: "For the longest time, we had no diabetes medications that reduce the risk of dying from heart disease… This is a sea change" (17:49).
• Christopher Davis, Everyday Wellness (Ep. 580, Apr 15): "I've never been a weight loss drug type of physician. However… the benefits… from a cardiovascular perspective, an MI risk, was pretty compelling." He added that "lifestyle still trumps everything" (49:13).
• Christian Ruff, ISTH Podcasts (Sep 16): GLP-1s have "revolutionized treatment of cardiovascular disease and obesity." He pointed to fewer heart attacks and strokes in landmark trials, and to emerging evidence on heart failure and kidney disease (2:18).
• Sirisha Vadali, GLP-1 Hub (Oct 12): "Even if you don't have diabetes and you have any kind of risk markers for cardio disease, you're protecting your heart with the GLP-1s" (3:00).
• Robert Califf (former FDA commissioner, no longer practicing), The Life Science Rundown (Oct 5): before GLP-1s, "almost all of the drugs that were tried for obesity had serious toxicities." He thinks the gut–brain biology being uncovered could also help with addiction, gambling and tobacco use (5:44).

2. Semaglutide vs. tirzepatide

• Vadali said the heart-risk reduction "has only been proven with Wegovy so far, semaglutide." Tirzepatide's heart-outcomes trial "didn't pan out," and a new one is coming (5:36).
• Asif Qasim, Move Well, Live Well, Perform Well (Jul 29): the hard outcome data, "fewer heart attacks and people live longer," came first with semaglutide. Trials with Mounjaro are still running (41:10).

3. Too few eligible patients get them

• Alexander J. Blood, 5-Minute Clinical Update and Grand Rounds (Aug 18): only a tiny share of anti-obesity prescriptions come from cardiologists. In his Brigham data, just 0.1% of patients who met the SELECT trial's criteria had an active semaglutide 2.4 prescription. He called this a "call to action" for cardiologists (25:30).
• Eimer credited Medicare's bridge program, which offers GLP-1s at $50 a month out of pocket, with "substantially" lowering cost barriers (14:07).

4. Concerns

• Adham Karim, Sarah Bush Lincoln Health Styles (Sep 2): he has taken patients off blood-pressure medicines after they lost 50–100 lbs. But "we're creating new problems": what happens when people stop the drug, what muscle loss means later, and "we don't know what happens if you've been on a GLP-1 for 20 years… there's this Pandora's box" (25:39).
• Qasim on off-label use by people who aren't overweight: "All the trial data is in overweight or obese people." He said a few years of use "gave you chronic pancreatitis or gave you diabetes… it's not unimaginable. And you wouldn't know it unless you ran the trial" (50:55). He also expects pills to be cheaper but less effective, and newer drugs like retatrutide to bring "more weight loss, slightly higher side effect profile" (52:34).
• Richard Fleming, The Podcast by KevinMD (May 25): "we're at the very beginning" of the data on GLP-1s and inflammation markers. His cardiology credential is marked unverified in the data (13:34).

These quotes come from the top 15 search matches, so this isn't a full count. Three of those matches with cardiologist guests were mostly about other drugs, so I left them out.